Shots:

• The company reported 2 new studies to evaluate adalimumab biosimilar SB5 for IBD including CD & UC and non-anterior uveitis associated with BS
• In a real-world study for IBD, 83.1% of patients switched from the reference product to biosimilar SB5. In the retrospective study on BS-associated uveitis, 8 patients treated with SB5 experienced complete resolution of inflammation @16mos.
• The 1EPs of the study was drug persistence. In the start & switch cohort, 137 patients (77.8%) & 213 patients (84.6%) remained on the biosimilar after 26wks, 65 (60.3%) & 163 (70.8%) were still being treated with SB5 @52wks. At a median follow-up of 18.3mos. & 13.7mos., 81 (36%) & 90 (35.2%) patients discontinued biosimilar treatment while 24 & 46 due to AES & 26 & 37 due to secondary loss of response, 22 due to primary non-response in the start cohort

Ref: Center for Biosimilars | Image: Samsung Bioepis